Annals of Clinical Microbiology, The official Journal of the Korean Society of Clinical Microbiology

6

Weeks in Review

4

Weeks to Publication
Indexed in KCI, KoreaMed, Synapse, DOAJ
Open Access, Peer Reviewed
pISSN 2288-0585 eISSN 2288-6850

Publishing policies

Annals of Clinical Microbiology is an open access, peer-reviewed journal committed to adhering to the following policies to enhance and maintain its high standards. It is available at https://www.acm.or.kr/for-contributors/instructions-to-authors/

Sections

Editorial policy

Peer review policy

Review and publication processes not described below follow the Editorial Policy Statements approved by the Council of Science Editors Board of Directors, available from https://www.councilscienceeditors.org/.

1. Screening before review

If the manuscript does not fit the aims and scope of the Journal or does not adhere to the Instructions for Authors, it may be returned to the author immediately after receipt, without review. Before reviewing, all submitted manuscripts are inspected by Similarity Check powered by iThenticate (https://www.crossref.org/services/similarity-check/), a plagiarism-screening tool. If the similarity score is too high, the Editorial Board will conduct a more detailed content screening. The similarity rate that triggers further screening is usually 15%; however, excessive similarity in specific sentences may also be checked in any manuscript. Similarity Check screening is set to exclude quotations, the bibliography, small matches of 6 words, small sources of 1%, and the Methods section.

2. Number of reviewers

The Editorial Board selects and recruits reviewers based on their expertise, publication history, and past reviews. It may consider reviewers recommended by the corresponding author. Manuscripts are peer reviewed by at least two experts in the relevant field. A third reviewer is assigned if there is a discrepancy between the two reviewers’ assessments.

3. Peer review process and the author response to the reviewer comments

ACM uses double-anonymous peer review. The author and reviewer cannot identify each other. The names of reviewers are not posted in the published article. The peer review process assesses the significance and originality of the research, the appropriateness of the approach or experimental design, and the validity of the conclusions and interpretations. The review period is 3 weeks. Usually the first decision is made within a week after completion of the review. The Editorial Board’s decision after review will be one of the following: Accept, Revision, or Reject.

The Editorial Board may request the authors to revise the manuscript according to the reviewers’ comments. Where reviewers request revisions, the authors should make every effort to comply. If a reviewer’s opinion is not acceptable or is believed to misinterpret the data, the author should say so, with reasons. After revising the manuscript, the author should upload the revised files with a point-by-point reply to the reviewers’ comments. The author’s revisions should be completed within 3 weeks after the request. If the revision is not received by the due date, the Editorial Board will notify the author. Any extension of the revision period beyond 3 weeks should be negotiated with the Editorial Board. The review process typically involves two rounds; additional rounds may be considered by the Editorial Board upon request. The Editorial Board will make a final decision on the approval of the submitted manuscript for publication and can request any further corrections, revisions, and deletions of the article text if necessary. Statistical editing is also performed where the data require professional review by a statistician.

4. Review process for in-house submissions

All manuscripts from editors, staff, or Editorial Board members are subject to the same review process as other submissions. During the review process, they will not be involved in the selection of reviewers or the decision-making process. Editors will not handle their own manuscripts, even if commissioned.

5. Processing after acceptance

Once a manuscript is accepted, proofs will be sent to the corresponding author after professional manuscript editing and English proofreading. The authors should check the proofs again for misspellings and other errors. Before final proofreading, the manuscript may appear on the journal homepage as an Epub ahead of print with a unique DOI for rapid communication. The Epub ahead of print version will be replaced by the final XML file and PDF.

6. How the journal handles complaints and appeals

The policy of ACM is primarily aimed at protecting the authors, reviewers, editors, and the publisher of the journal. If not described below, the process of handling complaints and appeals follows the guidelines of the Committee on Publication Ethics, available from: https://publicationethics.org/appeals.

Who complains or makes an appeal?

Submitters, authors, reviewers, and readers may register complaints and appeals in a variety of cases, including falsification, fabrication, plagiarism, duplicate publication, authorship disputes, conflicts of interest, the ethical treatment of animals, informed consent, bias or unfair or inappropriate competitive acts, copyright, stolen data, defamation, and legal problems. Individuals or institutions wishing to report such cases may send a letter via the contact page on the journal website: https://www.acm.or.kr. Complaints and appeals should be supported by concrete data answering all factual questions (who, when, where, what, how, and why).

Who is responsible for resolving and handling complaints and appeals?

The Editor, Editorial Board, or Editorial Office is responsible for handling them. A legal consultant or ethics editor may assist with decision-making.

What may be the consequence or remedy?

The consequence depends on the type and degree of misconduct and will follow the guidelines of the Committee on Publication Ethics (COPE).

Copyright & Open access policy

Copyright

Copyright to all published materials is owned by the Korean Society of Clinical Microbiology. The corresponding author should agree to the copyright transfer during the submission process. The Editorial Board assumes that the co-authors also accept the copyright transfer when the corresponding author does so; the corresponding author is responsible for submitting the copyright transfer agreement to the publisher.

Open Access policy

ACM is an open access journal, and all content published from June 2024 is freely available under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0, https://creativecommons.org/licenses/by-nc-nd/4.0/). Content published before June 2024 remains licensed under CC BY-NC 4.0 (https://creativecommons.org/licenses/by-nc/4.0/).

Under this license, users are free to share, that is, to copy and redistribute the material in any medium or format, under the following terms:

  • Attribution: You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the journal endorses you or your use.
  • NonCommercial: You may not use the material for commercial purposes.
  • NoDerivatives: If you remix, transform, or build upon the material, you may not distribute the modified material.

The following provisions describe the rights and conditions regarding access to, reuse of, and distribution of articles published in ACM.

  • Reader Access: All published articles are freely and immediately accessible to readers without subscription or payment.
  • Reuse: Unmodified articles may be copied and redistributed for noncommercial purposes, provided that appropriate credit is given and a link to the license is included. Distribution of modified versions is not permitted under the CC BY-NC-ND 4.0 license.
  • Author Posting: Authors may post the accepted manuscript (postprint) or the final published PDF, subject to the applicable license terms.
  • Automatic Posting: The publisher deposits accepted articles on the ACM homepage immediately (https://www.acm.or.kr) upon publication.

Article sharing policy (Self-archiving policy)

According to the deposit policy (self-archiving policy) of Sherpa/Romeo (https://www.sherpa.ac.uk/), authors may not archive the preprint (i.e., the version before refereeing), but may archive the postprint (i.e., the final draft after refereeing). Authors may also archive the publisher’s version or PDF.

Archiving policy

The full text of ACM is archived in the National Library of Korea (https://www.nl.go.kr/NL/contents/search.do?kwd=DTS20162180746#viewType=C&viewKey=DTS20162180746&jourId=DTS20162180746). ACM provides electronic backup and preserves access to the journal content in the event that the journal ceases publication.

Data sharing policy

ACM follows the data sharing policy described in “Data Sharing Statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors” (https://doi.org/10.3346/jkms.2017.32.7.1051). As of July 1, 2018, manuscripts reporting the results of clinical trials must include a data sharing statement. Additionally, clinical trials that begin enrolling participants on or after January 1, 2019, must include a data sharing plan in the trial’s registration. The ICMJE’s policy regarding trial registration is explained at https://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html.

To facilitate verification of the accuracy and reproducibility of study results, ACM encourages data sharing wherever possible, unless prevented by ethical, privacy, or confidentiality concerns.

Authors with inquiries about data deposition should contact the Editorial Office.

Preprint policy

ACM allows authors to submit preprints to the journal. This is not treated as duplicate submission or duplicate publication. When submitting a preprint, authors should provide information including the preprint server name, DOI or URL of the preprint, and the date of preprint publication. Authors must retain copyright for the manuscript so that it may be transferred to ACM if the manuscript is accepted, per the journal’s copyright policy. If the preprint is accepted for publication, authors are responsible for updating the preprint records with a link to the published article in ACM, including the DOI at ACM.

The process for handling cases requiring corrections, retractions, and editorial expressions of concern

ACM follows the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals by the International Committee of Medical Journal Editors (ICMJE) (http://www.icmje.org/icmje-recommendations.pdf) and the guidelines of the Committee on Publication Ethics (COPE) (https://publicationethics.org/guidance) for this process, if not described below:

ACM aims to ensure the integrity of the academic record of all published or potential publications. Whenever it is recognized that a significant inaccuracy, misleading statement, or distorted report has been published, it must be corrected promptly and with due prominence. If, after an appropriate investigation, an item proves to be fraudulent, it should be retracted. The retraction should be clearly identifiable to readers and indexing systems.

Errors in published papers may be identified in the form of a corrigendum or erratum when the Editor-in-Chief considers it appropriate to inform the journal readership about a previous error and makes a correction to the error in the published article. The corrigendum or erratum will appear as a new article in the journal and will cite the original published article.

An article may be retracted when the sincerity of the published work is undermined due to errors in the conduct, analysis, and/or reporting of the study. Violation of publication or research ethics may also result in a study’s retraction. The original article is marked as retracted, but a PDF version remains available to readers, and the retraction statement is bi-directionally linked to the original published paper. Retraction statements will typically include a statement of assent or dissent from the authors.

Where a certain amount of doubt arises as to the honesty or integrity of a submitted or published article, journal editors may issue an expression of concern. However, it should be issued only if an investigation into the article’s problems has been inconclusive and there are strong indicators that the concerns are valid.

Crossmark policy

Crossmark is an initiative to provide a standard way for readers to locate the current version of a piece of content. By applying the Crossmark button, ACM is committing to maintaining the content it publishes, and to alerting readers to changes if and when they occur. Clicking on the Crossmark button will tell readers the current status of a document, and may also give readers additional publication record information about the document (https://www.crossref.org/documentation/crossmark/crossmark-policy-page/).

Advertising policy

Advertisements may be displayed as banners on the ACM homepage, and the decision to accept them is made by the Korean Society of Clinical Microbiology. All advertisements are independent of editorial decisions.

Policies on the use of generative artificial intelligence (AI) in article writing and peer review

The use of artificial intelligence (AI)-assisted technologies, such as large language models, chatbots, and image generators, is permitted for language editing and preliminary drafting. Authors remain fully responsible for the accuracy, originality, and integrity of all submitted content, including any content generated with AI assistance. AI-assisted technologies must not be listed as authors or co-authors or cited as authors.

Authors must disclose the use of generative AI-assisted technologies in manuscript preparation, specifying the name of each tool and how it was used. If AI-assisted technologies are used for statistical analyses, data simulation, or other essential aspects of the research, authors must clearly disclose the name, version, and manufacturer of each tool, as well as its specific role in the research. The use of basic spelling and grammar checking tools does not require disclosure.